51693-17-5

Basic information

• Product Name: (S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone p-toluenesulfonate
• Synonyms: (S)-(+)-5-(HYDROXYMETHYL)-2-PYRROLIDINONE P-TOLUENESULFONATE;(S)-5-HYDROXYMETHYL-2-PYRROLIDINONE P-TOLUENESULFONATE;(-)-L-PYROGLUTAMOL P-TOLUENESULFONATE;(S)-(+)-5-(hydroxymethyl)-2-pyrrolidinone P-tolu;TOLUENE-4-SULFONIC ACID (S)-5-OXO-PYRROLIDIN-2-YLMETHYL ESTER;>98%ee;(S)-(+)-5-(HYDROXYMETHYL)-2-PYRROLIDINONE P-TOLUENESULFONATE 95%;(R)-(5-OXOPYRROLIDIN-2-YL)METHYL 4-METHYLBENZENESULFONATE
• CAS NO: 51693-17-5
• Molecular Formula: C₁₂H₁₅NO₄S
• Molecular Weight: 269.32
• Product Categories: Chiral Building Blocks;Heterocyclic Building Blocks;Pyrrolidines
• Mol File: 51693-17-5.mol

Chemical Properties

• Melting Point: 124-128 °C(lit.)
• Boiling Point: 504.8 °C at 760 mmHg
• Flash Point: 259.1 °C
• Appearance: Colorless to beige/Powder
• Density: 1.275 g/cm³
• Vapor Pressure: 2.58E-10mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: Refrigerator (+4°C)
• PKA: 15.34±0.40(Predicted)
• CAS DataBase Reference: (S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone p-toluenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone p-toluenesulfonate(51693-17-5)
• EPA Substance Registry System: (S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone p-toluenesulfonate(51693-17-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 51693-17-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone p-toluenesulfonate is used as a building block for the synthesis of (R)and (S)-diaminovaleric acids, which are essential components in the development of various pharmaceuticals. These diamines play a significant role in the creation of drugs targeting specific medical conditions, making (S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone p-toluenesulfonate a vital part of the pharmaceutical industry.
Used in Enantioselective Catalysis:
In the field of enantioselective catalysis, (S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone p-toluenesulfonate is used as a key component in the synthesis of 5-azasemicorrin bidentate nitrogen ligands. These ligands are crucial for the development of enantioselective catalysts, which are essential in producing chiral compounds with high selectivity and purity. This application is particularly important in the synthesis of pharmaceuticals, agrochemicals, and fine chemicals, where the enantiomeric purity of the product is critical.
Used in Chemical Research and Development:
(S)-(+)-5-(Hydroxymethyl)-2-pyrrolidinone p-toluenesulfonate is also utilized in chemical research and development, where its unique properties and reactivity are explored for the creation of new compounds and materials. Its versatility as a building block allows researchers to design and synthesize novel molecules with potential applications in various industries, including pharmaceuticals, materials science, and environmental science.

InChI:InChI=1/C12H15NO4S/c1-9-2-5-11(6-3-9)18(15,16)17-8-10-4-7-12(14)13-10/h2-3,5-6,10H,4,7-8H2,1H3,(H,13,14)/t10-/m0/s1

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 17342-08-4 (S)-Pyroglutaminol 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 56-86-0 L-glutamic acid 
• 32503-27-8 tetra(n-butyl)ammonium hydrogensulfate 
• 98-79-3 L-Pyroglutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 

Downstream Products

• 98334-22-6 (S)-1-acetyl-5-iodomethyl-pyrrolidin-2-one 
• 72479-06-2 2-[(2S)-5-oxopyrrolidin-2-yl]acetonitrile 
• 23506-90-3 4-[(8aS)-7-methyl-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol 
• 549548-39-2 (S)-6-(4-Benzyloxy-phenyl)-7-methyl-1,2,3,5,8,8a-hexahydro-indolizine 
• 549548-37-0 6-(4-benzyloxy-phenyl)-7-methyl-1,5,8,8a-tetrahydro-2H-indolizin-3-one 
• 549548-36-9 (S)-1-[2-(4-Benzyloxy-phenyl)-2-oxo-ethyl]-5-(2-oxo-propyl)-pyrrolidin-2-one 
• 549548-35-8 (S)-1-[2-(4-Benzyloxy-phenyl)-allyl]-5-(2-methyl-allyl)-pyrrolidin-2-one 
• 549548-38-1 (6S,7R,8aS)-6-(4-Benzyloxy-phenyl)-6,7-dihydroxy-7-methyl-hexahydro-indolizin-3-one 
• 173472-47-4 N-[(S)-1-(2-Amino-ethyl)-4-hydroxy-butyl]-4-methyl-benzenesulfonamide 
• 173472-45-2 [(S)-5-Oxo-1-(toluene-4-sulfonyl)-pyrrolidin-2-yl]-acetonitrile 
• 173472-46-3 (S)-5-Cyano-4-(toluene-4-sulfonylamino)-pentanoic acid methyl ester 
• 173472-38-3 N-[(S)-1-(2-Amino-ethyl)-4-(tert-butyl-diphenyl-silanyloxy)-butyl]-4-methyl-benzenesulfonamide 
• 173472-41-8 (2S,8S)-2-[3-(tert-Butyl-diphenyl-silanyloxy)-propyl]-1-(toluene-4-sulfonyl)-8-(2-triethylsilanyloxy-ethyl)-1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine 
• 173472-40-7 N-[(S)-4-(tert-Butyl-diphenyl-silanyloxy)-1-(2-{3-[(R)-1-(2-methylsulfanyl-ethyl)-3-triethylsilanyloxy-propyl]-thioureido}-ethyl)-butyl]-4-methyl-benzenesulfonamide 

Relevant articles and documents

Synthesis of N-aminomethylpyrrolidin-2-ones

Pyrrolidin-2-ones react with formaldehyde and chlorotrimethylsilane to give 1-chloromethylpyrrolidin-2-ones which upon subsequent reaction with primary and secondary amines give 1-aminomethylpyrrolidin-2-ones in good yield.

(S)-4-Amino-5-phenoxypentanoate designed as a potential selective agonist of the bacterial transcription factor GabR

Addressing molecular recognition in the context of evolution requires pursuing new molecular targets to enable the development of agonists or antagonists with new mechanisms of action. Disruption of transcriptional regulation through targeting transcription factors that regulate the expression of key enzymes in bacterial metabolism may provide a promising method for controlling the bacterial metabolic pathways. To this end, we have selectively targeted a bacterial transcription regulator through the design and synthesis of a series of γ-aminobutyric acid (GABA) derivatives, including (S)-4-amino-5-phenoxypentanoate (4-phenoxymethyl-GABA), which are based on docking insights gained from a previously-solved crystal structure of GabR from Bacillus subtilis. This target was selected because GabR strictly controls GABA metabolism by regulating the transcription of the gabT/D operon. These GabR transcription modulators are selective for the bacterial transcription factor GabR and are unable to bind to structural homologs of GabR due to distinct steric constraints. We have obtained a crystal structure of 4-phenoxymethyl-GABA bound as an external aldimine with PLP in the effector binding site of GabR, which suggests that this compound is capable of binding and reacting in the same manner as the native effector ligand. Inhibition assays demonstrate high selectivity of 4-phenoxymethyl-GABA for bacterial GabR versus several selected eukaryotic enzymes. Single-molecule fluorescence resonance energy transfer (smFRET) experiments reveal a ligand-induced DNA distortion that is very similar to that of the native effector GABA, suggesting that the compound functions as a potential selective agonist of GabR.

Photoredox-Catalyzed Synthesis of α-Amino Acid Amides by Imine Carbamoylation

An operationally simple protocol for the photocatalytic carbamoylation of imines is reported. Easily available, bench-stable 4-amido Hantzsch ester derivatives serve as precursors to carbamoyl radicals that undergo rapid addition to N-aryl imines. The reaction proceeds under blue light irradiation in the presence of the photocatalyst 3DPAFIPN and Br?nsted/Lewis acid additives. Mechanistic studies indicated a photoredox mechanism that involves carbamoyl radicals.

NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

Described herein are new, selective modulators of the 5 -HT7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors

Synthesis of optically active (R)- And (S)-β-arginine from pyroglutamic acid

– The first synthesis of optically active β-arginine was achieved starting from commercially available pyroglutamic acid. The new synthetic protocol is characterized by the use of nitrile as a carboxylic acid surrogate which could be transformed to the co

A class of histone acetylase p300 inhibitors, and application thereof

The invention discloses a class of histone acetylase p300 inhibitors, and application thereof, and belongs to the technical field of medicinal chemistry. The invention discloses a compound representedby a formula (I), or a stereochemical isomer, a solvate or a pharmaceutically acceptable salt thereof. According to the invention, the compound can effectively inhibit the activity of histone acetylase p300 and can effectively inhibit the proliferation activity of various tumor cells; the compound is combined with a CDK4/6 inhibitor to play a synergistic role in inhibiting proliferation of tumorcells; and the compound has good application prospects in preparation of histone acetylase inhibitors, preparation of drugs for preventing and/or treating cancers, metabolic diseases, neurological diseases or inflammations, and combination of drugs.

AMIDE DERIVATIVE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF

An amide derivative inhibitor and a preparation method and an application thereof. Specifically relating to the compound shown in general formula (I), a preparation method for same, a pharmaceutical composition comprising said compound, and an application of same as an ASK inhibitor for the treatment of neurodegenerative disease, cardiovascular disease, inflammation, autoimmune and metabolic disease, each of the substituents in the general formula (I) being as defined in the description.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5- hydroxytryptamine receptor 7 activity. A is selected